Orion Clinical

simbecorioncro.com

Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

TIMBER PHARMACEUTICALS TO BE ACQUIRED BY LEO PHARMA

Globenewswire | August 22, 2023

news image

Timber Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by LEO US Holding, Inc. a wholly-owned subsidiary of LEO Pharma A/S, in a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million and (ii) up to an additional $22.0 million in contingent value rights (CVRs) payable upon achievement of certain milestones described below. All of the issued and outstanding shares of capital stock and other equity ...

Read More

Research, Business Insights

ALLUCENT EXTENDS MEDIDATA CLINICAL CLOUD USAGE TO EXPEDITE NEW DRUG DEVELOPMENT

Medidata Solutions | March 13, 2023

news image

Medidata, a leading provider of innovative software solutions for clinical trials that streamline the clinical trial process, reduce time and cost, and accelerate the development of new treatments, recently announced that Allucent, a contract research organization (CRO) that brings innovation to biopharma firms, is expanding the global use of Medidata's Clinical Cloud to enhance its clinical trial operations offering. This agreement extends Allucent's current usage of Me...

Read More

Business Insights

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

news image

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

news image

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More
news image

PHARMACY MARKET, PHARMA TECH

TIMBER PHARMACEUTICALS TO BE ACQUIRED BY LEO PHARMA

Globenewswire | August 22, 2023

Timber Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by LEO US Holding, Inc. a wholly-owned subsidiary of LEO Pharma A/S, in a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million and (ii) up to an additional $22.0 million in contingent value rights (CVRs) payable upon achievement of certain milestones described below. All of the issued and outstanding shares of capital stock and other equity ...

Read More
news image

Research, Business Insights

ALLUCENT EXTENDS MEDIDATA CLINICAL CLOUD USAGE TO EXPEDITE NEW DRUG DEVELOPMENT

Medidata Solutions | March 13, 2023

Medidata, a leading provider of innovative software solutions for clinical trials that streamline the clinical trial process, reduce time and cost, and accelerate the development of new treatments, recently announced that Allucent, a contract research organization (CRO) that brings innovation to biopharma firms, is expanding the global use of Medidata's Clinical Cloud to enhance its clinical trial operations offering. This agreement extends Allucent's current usage of Me...

Read More
news image

Business Insights

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More
news image

COVID-19 AND SARS-COV-2 NEW RESEARCH, VACCINE AND DRUG DEVELOPMENT NEWS

BioTechniques | April 15, 2020

News covering COVID-19 is still to slow down, with this week’s big hitter being the announcement that US President Donald Trump has put funding for the WHO on hold pending a review. Accusing the WHO of “severely mismanaging and covering up” the threat, critics have been quick to respond, with the UN Secretary General António Guterres declaring now is “not the time to reduce the resources for the operations of the WHO…”. With the US contributing over $4...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us